Lithium and long-term cognitive outcomes in bipolar disorder and early dementia: a systematic review
CNS Spectrums · 2026 · 31 (1)
DOI: 10.1017/s1092852926100996 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift CNS Spectrums, online erschienen am 09.06.2026. Verfasst von Rosalyn Deng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Queen's University Faculty of Health Sciences, Canada. Hauptthemen laut MEDLINE: Bipolar Disorder, Lithium Compounds, Cognitive Dysfunction, Antimanic Agents. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
Cognitive impairment is a major determinant of disability in bipolar disorder (BD) and a defining feature of both mild cognitive impairment (MCI) and Alzheimer’s disease (AD). Lithium, a first-line maintenance treatment for BD, is implicated in neuroprotective mechanisms including glycogen synthase kinase-3β inhibition, amyloid and tau modulation, and neurogenesis promotion. The overarching aim of this systematic review is to evaluate the long-term effects of lithium on cognition across BD, MCI, and early-to-moderate AD using randomized controlled trial (RCT) evidence. Online databases were searched from inception through May 2025 for RCTs reporting lithium’s effect on cognitive outcomes in BD, MCI, or early-to-moderate AD with ≥8 weeks of follow-up. Risk of bias was assessed using the Cochrane RoB 2 tool. Eight RCTs met the inclusion criteria, ranging from 10 weeks to 3 years in duration. Across four BD trials, lithium did not exhibit consistent improvement or worsening on composite cognitive scores. Three of four MCI/AD trials reported attenuated global cognitive deterioration with low-dose lithium, especially when exposure was ≥12 months. Methodological limitations included small sample sizes, exploratory endpoints, and variable measures for cognitive function as well as lithium strategies. Lithium demonstrates preliminary signals of slower cognitive decline in MCI/AD. Available evidence suggests lithium has neutral effects on cognitive impairment in BD. Future adequately powered RCTs with cognition as a primary endpoint, functional measures, and biomarker outcomes are warranted to clarify lithium’s role as a maintenance treatment in psychiatric disorders and its potential neuroprotective effects in neurodegenerative diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Queen's University Faculty of Health Sciences, Canada.
- Brain and Cognition Discovery Foundation, Canada.
- Department of Human Biology, University of Toronto, Canada.
- University of Toronto Institute of Medical Science, Canada.
- Poul Hansen Family Centre for Depression, University Health Network, Canada.
- Department of Pharmacology, University of Toronto, Canada.
ORCID-Profile: Kayla Teopiz, Yang Jing Zheng, Roger S McIntyre
Zitieren
APA
Deng, R., Shargorodsky, A., Teopiz, K., Dri, C. E., Wong, S., Le, G. H., Zheng, Y. J., & McIntyre, R. S. (2026). Lithium and long-term cognitive outcomes in bipolar disorder and early dementia: a systematic review. CNS Spectrums, 31(1). https://doi.org/10.1017/s1092852926100996
Vancouver
Deng R, Shargorodsky A, Teopiz K, Dri CE, Wong S, Le GH, et al. Lithium and long-term cognitive outcomes in bipolar disorder and early dementia: a systematic review. CNS Spectrums. 2026;31(1). doi:10.1017/s1092852926100996
BibTeX
@article{Deng2026,
author = {Deng, Rosalyn and Shargorodsky, Alisa and Teopiz, Kayla and Dri, Christine E and Wong, Sabrina and Le, Gia Han and Zheng, Yang Jing and McIntyre, Roger S},
title = {Lithium and long-term cognitive outcomes in bipolar disorder and early dementia: a systematic review},
journal = {CNS Spectrums},
year = {2026},
volume = {31},
number = {1},
doi = {10.1017/s1092852926100996}
}
EUVIMED